A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT 05384626 Brief Summary Phase 1/2, dose escalation and expansion study designed…
Read more arrow_forwardNCT 05384626 Brief Summary Phase 1/2, dose escalation and expansion study designed…
Read more arrow_forwardNCT 03899792 Brief Summary This is an open-label, multi-center Phase 1/2 study…
Read more arrow_forwardNCT 03157128 Brief Summary This is an open-label, first-in-human study designed to…
Read more arrow_forwardNCT 06063681 Brief Summary This is an open-label, dose-escalation, multi-center phase 1…
Read more arrow_forwardNCT 05205109 Brief Summary This is a study of ATG-037 Monotherapy and…
Read more arrow_forwardNCT 04913285 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 05487235 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 04449874 Brief Summary This is a Phase I dose-escalation and dose-expansion…
Read more arrow_forwardNCT 06326411 Brief Summary This is a two-part Phase 1, open…
Read more arrow_forwardNCT 06533059 Brief Summary The purpose of this study is to characterize…
Read more arrow_forward